ARCHIVES

FDA Approves Abraxane For Second-Line Treatment Of Metastatic Breast Cancer

This article is from The Cancer Letter archive.

Vol. 28 No. 1 | January 28, 2005

Download PDF Visit The Full Archive

Related Articles

NIH Spent $181.3 Million on PR Last Year; House Probe Prompts Analysis of Spending

July 12, 2013

(8-page issue)

October 4, 2002

NCI Anticipates 60% Decline In Number Of New Trials By Cooperative Groups.

January 12, 2007

Breast Cancer Vs. Other Cancers In Budget Showdown

July 3, 1992

Nurses Must Assist In Pain Management, ONS Says

May 31, 1991

Endoscopic Surgery Provides Equal Or Better Results

September 30, 2005